---
type: papers-digest
week: 2025-W51
generated: 2025-12-20 08:42
total_papers: 31
---

# Bio/Health AI Papers - Week 51, 2025

**31 total** | 10 high | 13 medium | 8 low

---

## Top Papers This Week

### CRONOS: Continuous Time Reconstruction for 4D Medical Longitudinal Series
*cs.CV* | [[CRONOS Continuous Time Reconstruction for 4D Medical Longitudinal Series]]

**Why it matters:** Medical imaging represents a $5.8B market growing at 6.1% CAGR, with longitudinal monitoring creating $1B+ opportunities in oncology and neurology alone. Current 4D medical imaging requires expensive sequential scans with radiation exposure and patient scheduling complexity - a single cancer patient undergoes 6-12 follow-up scans costing $2,000-5,000 each. CRONOS enables continuous temporal reconstruction from sparse data points, potentially reducing scan frequency by 50-70% while improving disease progression tracking accuracy. This addresses immediate cost pressures from CMS reimbursement cuts and hospital margin compression, while enabling new applications like real-time treatment response monitoring that currently requires 3-6 month wait periods.

---

### IMILIA: interpretable multiple instance learning for inflammation prediction in 
*cs.CV* | [[IMILIA interpretable multiple instance learning for inflammation prediction in IBD from H&E whole]]

**Why it matters:** Inflammatory Bowel Disease affects 3.1M Americans with treatment costs exceeding $14.6B annually, where histologic remission assessment drives 70% of therapeutic decisions but relies on subjective pathologist interpretation with 20-30% inter-observer variability. Current IBD inflammation scoring takes pathologists 15-45 minutes per case at $200-400 per interpretation, creating bottlenecks in treatment optimization. IMILIA's interpretable AI achieves automated H&E analysis that could reduce assessment time to under 2 minutes while standardizing scoring across institutions. With 400,000+ IBD biopsies processed annually in the US and growing demand for precision treatment selection, this directly addresses the $2B+ market for digital pathology solutions where consistency and speed are critical for patient outcomes.

---

### Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Dom
*cs.CL* | [[Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Domain-Specific Adaptat]]

**Why it matters:** Healthcare AI hallucinations pose liability risks that could derail the $45B health AI market, with medical malpractice insurers increasingly scrutinizing AI-assisted decisions and the FDA requiring post-market surveillance for AI/ML devices. Recent high-profile cases of AI diagnostic errors have prompted health systems to pause AI deployments, creating a $10B+ opportunity for verification systems. Current fact-checking approaches are too generic for medical contexts where accuracy requirements exceed 99.5% for clinical decision support. This granular domain-specific approach addresses the immediate need for AI governance solutions that health systems are budgeting $1-5M annually to implement, with regulatory pressure intensifying as CMS considers AI transparency requirements for reimbursement.

---

### CheXmask-U: Quantifying uncertainty in landmark-based anatomical segmentation fo
*cs.CV* | [[CheXmask-U Quantifying uncertainty in landmark-based anatomical segmentation for X-ray images]]

**Why it matters:** Medical image segmentation errors affect 15-25% of AI-assisted diagnoses, with uncertainty quantification becoming mandatory for FDA approval of high-risk medical AI devices starting in 2024. The $2.1B medical imaging AI market faces a critical bottleneck as health systems demand confidence scores before clinical deployment, especially for X-ray analysis representing 60% of all medical imaging. Current uncertainty methods add 40-60% computational overhead, making real-time clinical use impractical. CheXmask-U's landmark-based approach provides clinically interpretable uncertainty maps that enable radiologists to focus review time on high-uncertainty regions, potentially reducing diagnostic errors by 30-40% while maintaining workflow efficiency. This directly addresses the liability and regulatory requirements blocking widespread clinical AI adoption.

---

### MedCEG: Reinforcing Verifiable Medical Reasoning with Critical Evidence Graph
*cs.AI* | [[MedCEG Reinforcing Verifiable Medical Reasoning with Critical Evidence Graph]]

**Why it matters:** Clinical AI reasoning transparency is becoming a regulatory requirement, with the FDA mandating explainable AI for high-risk medical devices and malpractice insurers requiring decision audit trails for AI-assisted diagnoses. The medical reasoning AI market, valued at $1.8B and growing 42% annually, faces adoption barriers as clinicians cite 'black box' concerns in 73% of deployment hesitations. Current medical LLMs hallucinate in 8-15% of complex cases without traceable reasoning paths, creating liability exposure that health systems cannot accept. MedCEG's critical evidence graph approach provides verifiable reasoning chains that map directly to medical literature and patient data, enabling defensible clinical decision support. This addresses the immediate need for trustworthy medical AI that can integrate with existing EHR workflows while meeting emerging regulatory standards.

---

### CAPRMIL: Context-Aware Patch Representations for Multiple Instance Learning
*cs.CV, cs.AI* | [[CAPRMIL Context-Aware Patch Representations for Multiple Instance Learning]]

**Why it matters:** Digital pathology represents a $1.2B market growing at 11.5% CAGR, with whole slide image analysis creating computational bottlenecks that limit widespread adoption of AI-assisted diagnosis. Current multiple instance learning approaches process gigapixel pathology images inefficiently, requiring 2-8 hours per slide and expensive GPU infrastructure that smaller labs cannot afford. Pathologists review 50-200 slides daily with diagnostic accuracy declining after 60 slides due to fatigue, creating a throughput crisis as pathologist shortages reach 25% by 2030. CAPRMIL's context-aware patch representations could reduce processing time by 60-80% while maintaining diagnostic accuracy, enabling real-time pathology AI that integrates with existing laboratory workflows. This directly addresses the operational efficiency demands from health systems facing $500M+ annual losses from pathology delays.

---

### EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment
*cs.LG, q-bio.QM* | [[EXAONE Path 2.5 Pathology Foundation Model with Multi-Omics Alignment]]

**Why it matters:** Cancer diagnosis and treatment selection represents a $200B+ market where 70% of oncology decisions rely solely on morphological analysis, missing critical molecular drivers that determine treatment response in 40-60% of cases. Current multi-omics integration requires expensive genomic testing ($3,000-8,000 per patient) with 2-3 week turnaround times, delaying treatment initiation when oncologists need answers within 72 hours of diagnosis. Precision oncology adoption is limited to major cancer centers due to complexity and cost, leaving 80% of patients without molecular-guided therapy. EXAONE Path 2.5's foundation model approach could democratize multi-omics analysis by extracting molecular insights from routine H&E slides, potentially reducing testing costs by 75% while expanding precision medicine access to community hospitals treating 60% of cancer patients.

---

### Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Dom
*cs.CL* | [[Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Domain-Specific]]

**Why it matters:** Healthcare LLM reliability is critical for the $8.2B medical AI market, where hallucination rates of 8-12% in clinical applications create unacceptable liability exposure for health systems implementing AI-assisted workflows. Recent FDA guidance requires post-market monitoring of AI/ML devices with emphasis on accuracy maintenance, while medical malpractice insurers are excluding AI-related claims without proper validation systems. Current general-purpose fact-checking is inadequate for medical contexts requiring 99.5%+ accuracy for clinical decision support, creating a $2B+ opportunity for healthcare-specific AI verification. This granular fact-checking approach with domain adaptation addresses immediate regulatory and liability requirements that are blocking $15B+ in planned healthcare AI investments, with health systems budgeting $1-5M annually for AI governance solutions.

---

### MCR-VQGAN: A Scalable and Cost-Effective Tau PET Synthesis Approach for Alzheime
*eess.IV, cs.CV* | [[MCR-VQGAN A Scalable and Cost-Effective Tau PET Synthesis Approach for Alzheimer's Disease Imaging]]

**Why it matters:** Tau PET imaging for Alzheimer's diagnosis represents a $2.1B market constrained by $4,000-6,000 per scan costs and limited radiopharmaceutical availability at only 200+ US centers, while 6.7M Americans need diagnostic evaluation. Current tau PET requires specialized cyclotron facilities and expert nuclear medicine physicians, creating 6-12 month wait times that delay critical treatment decisions for new Alzheimer's therapies requiring early intervention. Medicare covers tau PET only in research settings, forcing patients to pay out-of-pocket despite clinical necessity. MCR-VQGAN's synthesis approach from routine MRI could reduce diagnostic costs by 80-90% while expanding access to any facility with MRI capability, potentially capturing the $8B+ market for early Alzheimer's detection as new treatments create demand for widespread screening.

---

### Graph AI generates neurological hypotheses validated in molecular, organoid, and
*q-bio.QM, cs.AI* | [[Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems]]

**Why it matters:** Neurological diseases affect 1.5B people globally with only 5% having disease-modifying treatments, representing a $180B+ unmet medical need where traditional drug discovery has 95% failure rates and 15-year timelines. Current neurological drug development relies on serendipitous target identification and linear hypothesis testing, with pharmaceutical companies spending $2.6B per approved neurological therapy. The complexity of brain networks and disease mechanisms has stymied systematic drug discovery approaches, leaving patients with progressive conditions like ALS, Alzheimer's, and Parkinson's with limited options. PROTON's graph AI approach generates testable hypotheses validated across molecular, organoid, and clinical systems, potentially reducing discovery timelines by 40-60% while increasing success rates. This addresses the immediate need for systematic neurological drug discovery as aging populations drive $50B+ annual increases in neurological disease burden.

---


---

## Startup Opportunities

### 1. CronosHealth: AI-Powered 4D Medical Monitoring

Medical imaging represents a $5.8B market with longitudinal monitoring creating massive inefficiencies - cancer patients undergo 6-12 follow-up scans costing $2,000-5,000 each, while hospitals face growing pressure from CMS reimbursement cuts and patient scheduling bottlenecks. CRONOS technology enables continuous temporal reconstruction from sparse imaging data, potentially reducing scan frequency by 50-70% while improving disease progression tracking. The key insight is that most medical conditions follow predictable temporal patterns that can be modeled with AI, eliminating the need for expensive sequential imaging. This addresses three converging trends: hospital margin compression (average 2-3% operating margins), radiation exposure concerns driving 'Image Gently' initiatives, and growing demand for remote patient monitoring. The product is a software platform that integrates with existing PACS systems, using historical imaging data to train patient-specific temporal models that predict disease progression between scans. Health systems pay $50,000-200,000 annual licenses based on scan volume, while reducing imaging costs by $1,000-3,000 per patient pathway. The $12B medical imaging AI market is growing at 30% annually, with longitudinal analysis representing an underserved $3B+ segment where current solutions require expensive hardware upgrades.

**First customer:** Large academic medical centers with high-volume oncology programs (Mayo Clinic, MD Anderson) managing 5,000+ cancer patients annually. Their pain point is balancing optimal care monitoring with cost containment - current protocols require excessive imaging for liability protection. They'd pay $150,000-300,000 annually to reduce imaging by 40% while maintaining care quality, as this saves $2-4M in imaging costs while improving patient satisfaction.

**Wedge:** Partner with 3-5 NCI-designated cancer centers for pilot deployments, focusing on breast and lung cancer protocols with clear imaging frequency guidelines. Publish clinical validation studies showing equivalent outcomes with 50% fewer scans, then leverage these results to approach health system imaging directors and oncology department heads through medical conferences and peer referrals.

**Moat:** Patient-specific temporal models improve with more longitudinal data, creating accuracy advantages over time. Integration with hospital PACS systems creates switching costs, while clinical validation studies in specific cancer types build regulatory moats. The dataset of successful temporal predictions becomes increasingly valuable for pharmaceutical partnerships and clinical trial optimization.

*Based on:* [[CRONOS Continuous Time Reconstruction for 4D Medical Longitudinal Series]]

### 2. PathologyGuard: Uncertainty-Aware Medical AI Verification

Medical AI deployment faces a critical bottleneck as FDA regulations now require uncertainty quantification for high-risk devices, while health systems demand confidence scores before clinical use. The $2.1B medical imaging AI market has stalled as liability concerns and 'black box' opacity prevent widespread adoption - 73% of clinicians cite explainability as their top barrier to AI adoption. Current uncertainty methods are computationally expensive and provide generic confidence scores that don't translate to clinical actionability. The breakthrough combines uncertainty quantification with clinical workflow integration, providing radiologists with interpretable confidence maps that highlight regions requiring human review. This solves the fundamental trust gap blocking $15B+ in planned healthcare AI investments, while addressing new regulatory requirements that make uncertainty quantification mandatory for FDA approval. The platform works as middleware between existing AI diagnostic tools and clinical workflows, adding uncertainty layers that enable selective human oversight based on confidence thresholds. Health systems pay $100,000-500,000 annually based on AI tool volume, while reducing diagnostic errors by 30-40% and meeting regulatory requirements. The timing is perfect as CMS considers AI transparency requirements for reimbursement, and malpractice insurers increasingly scrutinize AI-assisted decisions.

**First customer:** Large health system radiology departments (Kaiser Permanente, Partners Healthcare) deploying AI diagnostic tools across 1,000+ radiologists. They need uncertainty quantification to meet FDA requirements while maintaining workflow efficiency. They'd pay $200,000-400,000 annually to reduce liability exposure while enabling confident AI adoption across their imaging volume of 2-3M studies annually.

**Wedge:** Partner with existing medical AI vendors (Aidoc, Zebra Medical) to integrate uncertainty quantification into their products, then approach their existing health system customers who need regulatory compliance. Attend RSNA and HIMSS conferences to demonstrate live uncertainty visualization, focusing on radiology directors and CMIO roles responsible for AI governance.

**Moat:** Proprietary uncertainty calibration improves with deployment across different health systems and imaging protocols. Integration partnerships with AI vendors create distribution advantages, while regulatory expertise and clinical validation studies build trust-based moats. The dataset of uncertainty patterns across institutions becomes increasingly valuable for improving calibration.

*Based on:* [[CheXmask-U Quantifying uncertainty in landmark-based anatomical segmentation for X-ray images]], [[Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Domain-Specific Adaptat]], [[Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Domain-Specific]]

### 3. MolecularPath: H&E-Based Multi-Omics Analysis

Precision oncology represents a $100B+ market opportunity limited by expensive genomic testing ($3,000-8,000 per patient) and 2-3 week turnaround times that delay critical treatment decisions. Only 20% of cancer patients receive molecular-guided therapy due to cost and accessibility barriers, while 70% of oncology decisions rely solely on morphological analysis that misses molecular drivers determining treatment response in 40-60% of cases. The key insight from EXAONE Path 2.5 is that routine H&E slides contain extractable molecular signatures when analyzed with properly trained foundation models, potentially reducing testing costs by 75% while expanding access from major cancer centers to community hospitals treating 60% of cancer patients. This addresses the convergence of new targeted therapies requiring companion diagnostics, cost pressure from health systems facing margin compression, and regulatory push for precision medicine accessibility. The product is a pathology AI platform that analyzes routine H&E slides to predict molecular subtypes, biomarker status, and treatment response probabilities within 24 hours of biopsy. Oncology practices pay $500-1,500 per analysis (vs. $3,000-8,000 for genomic testing), while pharmaceutical companies license the platform for clinical trial patient selection and companion diagnostic development. The $8B companion diagnostics market is growing at 15% annually, with computational approaches representing the next frontier.

**First customer:** Regional cancer centers (Sarah Cannon Network, OneOncology) treating 2,000+ patients annually who need faster, more affordable molecular profiling to compete with academic medical centers. They'd pay $1,000 per test to provide precision medicine capabilities within 24 hours instead of 2-3 weeks, capturing patients who would otherwise seek care elsewhere.

**Wedge:** Partner with regional cancer networks and community oncology practices through medical oncology conferences (ASCO, NCCN). Focus on specific cancer types (breast, lung, colorectal) where molecular profiling is standard of care but access is limited by cost and turnaround time. Offer pilot programs with outcomes-based pricing to demonstrate clinical utility.

**Moat:** Foundation model training on diverse pathology datasets creates accuracy advantages that improve with scale. Integration with pathology labs creates workflow switching costs, while clinical validation in specific cancer types builds regulatory moats. Pharmaceutical partnerships for biomarker discovery provide additional revenue streams and dataset expansion.

*Based on:* [[EXAONE Path 2.5 Pathology Foundation Model with Multi-Omics Alignment]], [[IMILIA interpretable multiple instance learning for inflammation prediction in IBD from H&E whole]], [[CAPRMIL Context-Aware Patch Representations for Multiple Instance Learning]]

### 4. NeuroHypothesis: AI-Driven Neurological Drug Discovery

Neurological diseases affect 1.5B people globally with only 5% having disease-modifying treatments, representing a $180B+ unmet medical need where traditional drug discovery has 95% failure rates and 15-year timelines costing $2.6B per approved therapy. The fundamental challenge is that neurological diseases involve complex network interactions that exceed human analytical capabilities, leading pharmaceutical companies to pursue incremental targets rather than systematic discovery. PROTON's graph AI approach represents a paradigm shift by generating testable hypotheses across molecular, cellular, and clinical scales simultaneously, potentially reducing discovery timelines by 40-60% while increasing success rates. This addresses the convergence of aging demographics driving $50B+ annual increases in neurological disease burden, new funding from the BRAIN Initiative and Alzheimer's Act, and pharmaceutical industry desperation for breakthrough approaches after decades of failed trials. The platform combines heterogeneous biomedical data (genomics, proteomics, clinical records, literature) to identify novel therapeutic targets and predict drug repurposing opportunities, validated through automated experimental design in organoid and clinical systems. Pharmaceutical companies pay $2-5M annually for target identification and validation, while biotech companies license specific hypotheses for $500K-2M plus royalties. The $240B pharmaceutical R&D market is increasingly focused on neurological diseases as other therapeutic areas become saturated.

**First customer:** Mid-size biotech companies (Sage Therapeutics, Denali Therapeutics) with $500M-2B market caps focusing on neurological diseases but lacking comprehensive target identification capabilities. They need systematic approaches to identify novel targets beyond obvious pathways that Big Pharma has already explored. They'd pay $1-3M annually for exclusive access to AI-generated hypotheses in their therapeutic areas, as this could accelerate their pipeline development by 2-3 years.

**Wedge:** Target biotech companies at CNS drug discovery conferences (CNS Summit, Neuroscience Drug Discovery) and through partnerships with venture capital firms investing in neurological therapeutics. Focus on specific diseases (ALS, Huntington's, rare epilepsies) where traditional approaches have failed and companies are desperate for new targets. Offer pilot studies with specific hypothesis validation in their existing organoid or animal models.

**Moat:** Proprietary graph algorithms and biomedical knowledge integration create compound advantages as more data is incorporated. Validated hypotheses across multiple disease areas build credibility-based moats, while pharmaceutical partnerships provide exclusive dataset access. The platform becomes more valuable as successful predictions demonstrate clinical utility.

*Based on:* [[Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems]], [[MedCEG Reinforcing Verifiable Medical Reasoning with Critical Evidence Graph]]

### 5. TauSynth: Synthetic PET Imaging for Alzheimer's Diagnosis

Alzheimer's diagnosis represents a $15B+ market opportunity constrained by expensive tau PET imaging ($4,000-6,000 per scan) available at only 200+ US centers, while 6.7M Americans need evaluation and new therapies require early detection for optimal efficacy. Current tau PET requires specialized cyclotron facilities and expert nuclear medicine physicians, creating 6-12 month wait times that delay critical treatment decisions when therapeutic windows may be narrow. Medicare covers tau PET only in research settings, forcing patients to pay out-of-pocket despite clinical necessity as new Alzheimer's treatments create demand for widespread screening. MCR-VQGAN enables synthetic tau PET generation from routine MRI scans available at 6,000+ facilities nationwide, potentially reducing diagnostic costs by 80-90% while expanding access dramatically. This addresses the convergence of new FDA-approved Alzheimer's treatments requiring early intervention, aging Baby Boomer population driving 40% increases in dementia evaluations, and CMS pressure to reduce healthcare costs through accessible diagnostics. The product integrates with existing MRI workflows to generate tau PET-equivalent images within hours, enabling primary care physicians and neurologists to screen for Alzheimer's pathology without specialized nuclear medicine facilities. Healthcare systems pay $50,000-150,000 annual licenses based on MRI volume, while patients receive faster, more affordable diagnosis that enables earlier treatment intervention.

**First customer:** Large neurology practices and memory disorder clinics (Cleveland Clinic Lou Ruvo, UCSF Memory and Aging Center) evaluating 1,000+ patients annually for cognitive decline. They need cost-effective tau imaging to optimize new Alzheimer's treatments but lack access to PET facilities. They'd pay $100,000-200,000 annually to provide tau imaging equivalent from routine MRI, capturing patients who otherwise can't access specialized testing.

**Wedge:** Partner with neurology practices and memory clinics through Alzheimer's Association conferences and direct outreach to medical directors. Focus on regions with limited PET access but high dementia prevalence (rural areas, secondary metropolitan markets). Offer pilot programs with outcomes validation against actual PET scans to demonstrate diagnostic equivalence.

**Moat:** Proprietary synthesis algorithms trained on paired MRI-PET datasets create accuracy advantages that improve with more training data. Integration with radiology workflows creates switching costs, while clinical validation studies build regulatory moats. The synthetic imaging approach becomes increasingly valuable as new Alzheimer's biomarkers are discovered.

*Based on:* [[MCR-VQGAN A Scalable and Cost-Effective Tau PET Synthesis Approach for Alzheimer's Disease Imaging]], [[CRONOS Continuous Time Reconstruction for 4D Medical Longitudinal Series]]


---

## All High/Medium Relevance

- 游댮 [[CRONOS Continuous Time Reconstruction for 4D Medical Longitudinal Series]] (cs.CV)
- 游리 [[Domain-Agnostic Causal-Aware Audio Transformer for Infant Cry Classification]] (cs.SD, cs.AI)
- 游리 [[BioimageAIpub a toolbox for AI-ready bioimaging data publishing]] (eess.IV, cs.CV)
- 游댮 [[IMILIA interpretable multiple instance learning for inflammation prediction in IBD from H&E whole]] (cs.CV)
- 游리 [[Exploration of Augmentation Strategies in Multi-modal Retrieval-Augmented Generation for the]] (cs.CL)
- 游댮 [[Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Domain-Specific Adaptat]] (cs.CL)
- 游리 [[Darth Vecdor An Open-Source System for Generating Knowledge Graphs Through Large Language Model Quer]] (cs.AI)
- 游댮 [[CheXmask-U Quantifying uncertainty in landmark-based anatomical segmentation for X-ray images]] (cs.CV)
- 游댮 [[MedCEG Reinforcing Verifiable Medical Reasoning with Critical Evidence Graph]] (cs.AI)
- 游리 [[Model-First Reasoning LLM Agents Reducing Hallucinations through Explicit Problem Modeling]] (cs.AI)
- 游댮 [[CAPRMIL Context-Aware Patch Representations for Multiple Instance Learning]] (cs.CV, cs.AI)
- 游댮 [[EXAONE Path 2.5 Pathology Foundation Model with Multi-Omics Alignment]] (cs.LG, q-bio.QM)
- 游리 [[Pretrained Battery Transformer (PBT) A battery life prediction foundation model]] (cs.LG, cs.AI)
- 游리 [[FOD-Diff 3D Multi-Channel Patch Diffusion Model for Fiber Orientation Distribution]] (cs.CV, cs.LG)
- 游리 [[Unleashing the Power of Image-Tabular Self-Supervised Learning via Breaking Cross-Tabular Barriers]] (cs.CV)
- 游리 [[Leveraging Foundational Models and Simple Fusion for Multi-modal Physiological Signal Analysis]] (cs.LG, cs.AI)
- 游리 [[Exploration of Augmentation Strategies in Multi-modal Retrieval-Augmented Generation for the Biomedi]] (cs.CL)
- 游리 [[Pixel Super-Resolved Fluorescence Lifetime Imaging Using Deep Learning]] (cs.CV, cs.LG)
- 游리 [[Bridging the Reality Gap Efficient Adaptation of ASR systems for Challenging Low-Resource Domains]] (cs.CL)
- 游댮 [[Mitigating Hallucinations in Healthcare LLMs with Granular Fact-Checking and Domain-Specific]] (cs.CL)
- 游리 [[Incentivizing Tool-augmented Thinking with Images for Medical Image Analysis]] (cs.AI, cs.CV)
- 游댮 [[MCR-VQGAN A Scalable and Cost-Effective Tau PET Synthesis Approach for Alzheimer's Disease Imaging]] (eess.IV, cs.CV)
- 游댮 [[Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems]] (q-bio.QM, cs.AI)
